Trials / Conditions / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

11 registered clinical trials studyying Leukemia, Lymphoblastic, Acute, Philadelphia-Positive — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Pos NCT07387926	Novartis Pharmaceuticals	Phase 1 / Phase 2
Unknown	Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph NCT05495035	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Terminated	Acute Lymphoblastic Leukemia Registry at Asan Medical Center NCT01761682	Asan Medical Center	—
Terminated	Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors NCT01100658	University of Minnesota	N/A
Completed	Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia NCT01310010	Grupo Espanol de trasplantes hematopoyeticos y terapia celular	Phase 2
Terminated	Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) NCT00907517	Merck Sharp & Dohme LLC	Phase 1
Terminated	A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelph NCT00500006	Merck Sharp & Dohme LLC	Phase 1
Terminated	Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic NCT00464113	Exelixis	Phase 1
Completed	Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML NCT00123487	Bristol-Myers Squibb	Phase 3
Completed	Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromoso NCT00101595	Bristol-Myers Squibb	Phase 2
Completed	BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia P NCT00103701	Bristol-Myers Squibb	Phase 1